La información sobre Esclerosis Múltiple que in-pacient.es pone a tu disposición está basada en las fuentes bibliográficas que se citan a continuación, así como en la propia experiencia del Comité Editorial y revisores de in-pacient.es  Además ésta se revisa de forma periódica por dicho Comité  Editorial, con el fin de mantenerla actualizada.

Los enlaces dirigidos a páginas web pueden no estar disponibles por causas ajenas a nuestra voluntad, por lo que pedimos disculpas y agradeceremos que nos informes de estas anomalías para poder subsanarlas a través del siguiente formulario

Referencias:

 

Abad P et al.
[LACTRIMS consensus document for the pharmacological treatment of the multiple sclerosis and its clinical variants].
Rev Neurol. 2012 Dec 16;55(12):737-48

Andersen O.
Predicting a window of therapeutic opportunity in multiple sclerosis.
Brain. 2010 Jul;133(Pt 7):1863-5

Andrews CN et al.
The pathophysiology of chronic constipation.
Can J Gastroenterol. 2011 Oct;25 Suppl B:16B-21B

Artemiadis AK et al.
Stress as a risk factor for multiple sclerosis onset or relapse: a systematic review.
Neuroepidemiology. 2011;36(2):109-20

Asano M et al.
Meta-analysis of three different types of fatigue management interventions for people with multiple sclerosis: exercise, education, and medication.
Mult Scler Int. 2014;2014:798285

Ascherio A et al.
Vitamin D as an early predictor of multiple sclerosis activity and progression.
JAMA Neurol. 2014;71(3):306-314.

Bäärnhielm M et al.
Fatty fish intake is associated with decreased occurrence of multiple sclerosis.
Mult Scler 2014;20(6) 726–732

Bagnato F et al.
Painful and involuntary multiple sclerosis.
Expert Opin Pharmacother. 2011 Apr;12(5):763-77

Barret CL et al.
A randomized trial to investigate the effects of functional electrical stimulation and therapeutic exercise on walking performance for people with multiple sclerosis.
Multiple Sclerosis 2009;15(4):493-504.

Berkovich R.
Treatment of acute relapses in multiple sclerosis.
Neurotherapeutics. 2013 Jan;10(1):97-105

Bitarafan S et al.
Dietary intake of nutrients and its correlation with fatigue in multiple sclerosis patients.
Iran J Neurol. 2014;13(1):28-32.

Cantorna MT.
Vitamin D, multiple sclerosis and inflammatory bowel disease.
Arch Biochem Biophys. 2012 Jul 1;523(1):103-6.

Derakhshandi H et al.
Preventive effect of vitamin D3 supplementation on conversion of optic neuritis to clinically definite multiple sclerosis: a double blind, randomized, placebo-controlled pilot clinical trial.
Acta Neurol Belg. 2013 Sep;113(3):257-63.

Duan S et al.
Vitamin D status and the risk of multiple sclerosis: a systematic review and meta-analysis.
Neurosci Lett. 2014 Jun 6;570:108-13

Elbers RG et al.
Self-report fatigue questionnaires in multiple sclerosis, Parkinson’s disease and stroke: a systematic review of measurement properties.
Qual Life Res. 2012 Aug;21(6):925-44

European Food Safety Authority (EFSA) Panel on Dietetic Products, Nutrition and allergies.
Scientific Opinion on the Tolerable Upper Intake Level of vitamin D.
EFSA Journal 2012;10(7):2813

Farez MF et al.
Sodium intake is associated with increased disease activity in multiple sclerosis.
J Neurol Neurosurg Psychiatry. 2014 Aug 28. doi:10.1136/jnnp-2014-307928

Faridar A et al.
Vitamin D and multiple sclerosis: a critical review and recommendations on treatment.
Acta Neurol Belg. 2012;112(4):327-33.

Feinstein A et al.
The link between multiple sclerosis and depression.
Nat Rev Neurol. 2014 Sep;10(9):507-17

Fernández O et al.
Biomarcadores en la esclerosis múltiple: puesta al día 2014.
Rev Neurol 2014; 58 (12): 553-570.

Ferreira ML
Cognitive deficits in multiple sclerosis: a systematic review.
Arq Neuropsiquiatr. 2010 Aug;68(4):632-41

Finkelsztejn A et al.
Latin American algorithm for treatment of relapsing-remitting multiple sclerosis using disease-modifying agents.
Arq Neuropsiquiatr. 2012 Oct;70(10):799-806

Fode M et al.
Male sexual dysfunction and infertility associated with neurological disorders.
Asian J Androl. 2012 Jan;14(1):61-8

García Merino A et al.
[Spanish Neurology Society consensus document on the use of drugs in multiple sclerosis: escalating therapy].
Neurologia. 2010 Jul-Aug;25(6):378-90

Gómez-Soriano J et al.
[Evaluation and quantification of spasticity: a review of the clinical, biomechanical and neurophysiological methods].
Rev Neurol. 2012 Aug 16;55(4):217-26

Gonsette RE
Self-tolerance in multiple sclerosis.
Acta Neurol Belg. 2012 Jun;112(2):133-40

Guo ZN et al.
Multiple sclerosis and sexual dysfunction.
Asian J Androl. 2012 Jul;14(4):530-5

Gupta S et al.
Osteoporosis and multiple sclerosis: risk factors, pathophysiology, and therapeutic interventions.
CNS Drugs. 2014 Aug;28(8):731-42.

Handel AE et al.
Smoking and multiple sclerosis: an updated meta-analysis.
PLoS One. 2011 Jan 13;6(1):e16149

Healy BC et al.
Smoking and Disease Progression in Multiple Sclerosis.
Arch Neurol. 2009;66(7):858-864.

Hedström AK et al.
Mult Scler. 2014 Apr;20(4):445-50.
Smoking and risk of treatment-induced neutralizing antibodies to interferon β-1a.

Holmøy T et al.
Vitamin D in multiple sclerosis: implications for assessment and treatment.
Expert Rev Neurother. 2012;12(9):1101-12.

Jagannath VA et al.
Vitamin D for the management of multiple sclerosis.
Cochrane Database Syst Rev. 2010;(12):CD008422.


Kampman MT et al.
Multiple sclerosis, a cause of secondary osteoporosis? What is the evidence and what are the clinical implications?
Acta Neurol Scand Suppl. 2011;(191):44-9.

Kampman MT et al.
Effect of vitamin D3 supplementation on relapses, disease progression, and measures of function in persons with multiple sclerosis: exploratory outcomes from a double-blind randomised controlled trial.
Mult Scler. 2012;18(8):1144-51.

Keough MB et al.
Remyelination therapy for multiple sclerosis.
Neurotherapeutics. 2013 Jan;10(1):44-54

Langdon DW et al.
Recommendations for a Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS).
Mult Scler. 2012 Jun;18(6):891-8

Langer-Gould A et al.
Vaccines and the Risk of Multiple Sclerosis and Other Central Nervous System Demyelinating Diseases.
JAMA Neurol. 2014 Oct 20. doi: 10.1001/jamaneurol.2014.2633. [Epub ahead of print]

Langer-Gould AM
The pill times 2: what every woman with multiple sclerosis should know.
Neurology. 2014 Feb 25;82(8):654-5

Lew-Starowicz M et al.
Prevalence of Sexual Dysfunctions Among Women with Multiple Sclerosis.
Sex Disabil. 2013 Jun;31(2):141-153

Malik MT et al.
Factors associated with recovery from acute optic neuritis in patients with multiple sclerosis.
Neurology 2014;82(24):2173–2179

Marck CH et al.
Physical activity and associated levels of disability and quality of life in people with multiple sclerosis: a large international survey.
BMC Neurol. 2014;14:143.

Martinelli V et al.
Vitamin D levels and risk of multiple sclerosis in patients with clinically isolated syndromes.
Mult Scler 2014 20(2): 147-155

Massa J et al.
Caffeine and alcohol intakes have no association with risk of multiple sclerosis.
Mult Scler. 2013 Jan;19(1):53-8

Miller L et al.
The effects of transcutaneous electrical nerve stimulation (TENS) on spasticity in multiple sclerosis.
Multiple Sclerosis 2007; 13: 527-533.

Mohammadi K et al.
Determinants of sexual dysfunction in women with multiple sclerosis.
BMC Neurol. 2013 Jul 12;13(1):83

Munger KL et al.
Prevention and treatment of MS: studying the effects of vitamin D.
Mult Scler. 2011 Dec;17(12):1405-11

Nylander A et al.
Multiple sclerosis.
J Clin Invest. 2012 Apr 2;122(4):1180-8

Olascoaga J
[Quality of life and multiple sclerosis].
Rev Neurol. 2010 Sep 1;51(5):279-88

Opara JA et al.
Quality of life in multiple sclerosis.
J Med Life. 2010 Oct-Dec;3(4):352-8

Otero-Romero S et al.
Recommendations for vaccination in patients with multiple sclerosis who are eligible for immunosuppressive therapies: Spanish consensus statement [published online ahead of print, 2020 Jun 17]. Recomendaciones para la vacunación en pacientes con esclerosis múltiple candidatos a terapias inmunosupresoras: documento de consenso español [published online ahead of print, 2020 Jun 17]. Neurologia. 2020;S0213-4853(20)30045-1.

Owens GP et al.
Viruses and multiple sclerosis.
Neuroscientist. 2011 Dec;17(6):659-76

Paltamaa J et al.
Effects of physiotherapy interventions on balance in multiple sclerosis: a systematic review and meta-analysis of randomized controlled trials.
J Rehabil Med. 2012 Oct;44(10):811-23

Pierrot-Deseilligny C et al.
Is hypovitaminosis D one of the environmental risk factors for multiple sclerosis?
Brain. 2010 Jul;133(Pt 7):1869-88

Pozuelo-Moyano B et al.
A systematic review of randomized, double-blind, placebo-controlled trials examining the clinical efficacy of vitamin D in multiple sclerosis.
Neuroepidemiology. 2013;40(3):147-53

Pozuelo-Moyano B et al.
[Vitamin D and multiple sclerosis].
Rev Neurol. 2013 Feb 16;56(4):243-51

Pozuelo-Moyano B et al.
A Systematic Review of Randomized, Double-Blind, Placebo-Controlled Trials Examining the Clinical Efficacy of Vitamin D in Multiple Sclerosis.
Neuroepidemiology. 2013;40(3):147-53

Rae-Grant AD et al.
Self-management in neurological disorders: systematic review of the literature and potential interventions in multiple sclerosis care.
J Rehabil Res Dev. 2011;48(9):1087-100

Rose A. Living with the effects of MS. MS Essentials, Multiple Sclerosis Society. 1ª Ed. Revisada Octubre 2014

Rotstein DL et al.
Dietary patterns not associated with the risk of multiple sclerosis.
MS Boston 2014: The 2014 Joint Americas and European Committees for Treatment and Research in Multiple Sclerosis (ACTRIMS/ECTRIMS) meeting. Abstracts PS5.1, PS5.3, and P055. Presented September 11, 2014

Sandroff BM et al.
Randomized controlled trial of physical activity, cognition, and walking in multiple sclerosis.
J Neurol. 2014 Feb;261(2):363-72

Soilu-Hänninen M et al.
A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon β-1b in patients with multiple sclerosis.
J Neurol Neurosurg Psychiatr. 2012;83(5):565-71.

Sperandeo K et al.
Managed approaches to multiple sclerosis in special populations.
J Manag Care Pharm. 2011 Nov-Dec;17(9 Suppl C):S1-19

Spooren AI et al.
Motor training programs of arm and hand in patients with MS according to different levels of the ICF: a systematic review.
BMC Neurol. 2012 Jul 2;12:49

Varo-Sánchez GM et al.
[Pharmacological targets in multiple sclerosis].
Rev Neurol. 2011 Jul 1;53(1):27-34

Vijayshree Y, et al.
Summary of evidence-based guideline: Complementary and alternative medicine in multiple sclerosis Report of the Guideline Development Subcommittee of the American Academy of Neurology.
Neurology 2014 Mar 25;82(12):1083-92.

Wingerchuk DM et al.
Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies
Mayo Clin Proc. 2014 Feb;89(2):225-40

Young CA
Factors predisposing to the development of multiple sclerosis.
QJM. 2011 May;104(5):383-6